Clinical Trials
Currently we are performing clinical investigations of novel CAR-T and TIL therapies in multiple disease areas including hematological malignancies, solid tumors and inflammatory and immunological diseases.
Product | Indication | Clinical Study | NCT NUMBER(s) | PUBLICATION/PRESENTATION |
---|---|---|---|---|
C-CAR039 | r/r B-NHL | Investigator-initiated trial in China | NCT04317885 | |
NCT04655677 | ||||
NCT04696432 | ||||
NCT04693676 | ||||
Phase 1b/2 trial in China | NCT05800977 | |||
Phase 1b trial worldwide (ex-Greater China) licensed to JNJ | NCT05421663 |
|
||
C-CAR066 | r/r B-NHL including prior CAR-T | Investigator-initiated trial in China | NCT04036019 | |
Phase 1b trial worldwide (ex-Greater China) licensed to JNJ | NCT05784441 |
|
||
C-CAR088 | r/r Multiple Myeloma | Phase 1b/2 trial in China | NCT05521802 | |
Investigator-initiated trial in China | NCT04322292 | Journal for Immunotherapy of Cancer 09/2022 | ||
NCT03815383 | ||||
NCT03751293 | ||||
NCT04295018 | ||||
C-CAR031 | Hepatocellular Carcinoma (HCC) | Investigator-initiated trial in China | NCT05155189 | |
C-TIL051 | Non Small Cell Lung Cancer (NSCLC) | Phase 1 trial US | NCT05676749 |